0000950170-23-010435 | 10-K | XBRL Viewer

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2022	Mar. 24, 2023	Sep. 19, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Entity Registrant Name	THIRD HARMONIC BIO, INC.
Entity Central Index Key	0001923840
Entity File Number	001-41498
Entity Tax Identification Number	83-4553503
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Incorporation, State or Country Code	DE
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Address, Address Line One	1700 Montgomery Street
Entity Address, Address Line Two	Suite 210
Entity Address, State or Province	CA
Entity Address City Or Town	San Francisco
Entity Address, Postal Zip Code	94111
City Area Code	209
Local Phone Number	727-2457
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
ICFR Auditor Attestation Flag	false
Entity Common Stock, Shares Outstanding		40,324,215
Entity Public Float			$ 388.0
Trading Symbol	THRD
Security Exchange Name	NASDAQ
Documents Incorporated By Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s Definitive Proxy Statement relating to the 2023 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. The Definitive Proxy Statement will be filed within 120 days of the Registrant’s fiscal year ended December 31, 2022. Except with respect to information specifically incorporated by reference in this Form 10-K, the Definitive Proxy Statement is not deemed to be filed as part of this Annual Report on Form 10-K.
Auditor Name	Deloitte & Touche LLP
Auditor Firm ID	34
Auditor Location	Morristown, New Jersey

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 288,877,000	$ 128,280,000
Prepaid expenses and other current assets	3,958,000	884,000
Total current assets	292,835,000	129,164,000
Restricted cash	441,000	0
Property and equipment, net	35,000	0
Right of use asset	4,327,000	0
Other assets	1,037,000	0
Total assets	298,675,000	129,164,000
Current liabilities:
Accounts payable	2,087,000	1,797,000
Accrued Expense And Other Current Liabilities	3,181,000	3,889,000
Operating lease liability, current	385,000	0
Total current liabilities	5,653,000	5,686,000
Operating lease liability, noncurrent	3,954,000	0
Preferred stock tranche liability	0	0
Anti-dilution liability	0	0
Total liabilities	9,607,000	5,686,000
Commitments and contingencies (Note 13)
Redeemable convertible preferred stock		170,184,000
Stockholders’ deficit:
Common stock, $0.0001 par value, 72,731,000 and 500,000,000 shares authorized at December 31, 2021 and December 31, 2022; 4,237,290 and 39,377,222 shares issued and outstanding at December 31, 2021 and December 31, 2022, respectively	4,000	1,000
Preferred stock, $0.0001 par value, - and 10,000,000 shares authorized at December 31, 2021 and December 31, 2022; - and - shares issued and outstanding at December 31, 2021 and December 31, 2022, respectively
Additional paid-in capital	372,460,000	1,534,000
Accumulated deficit	(83,396,000)	(48,241,000)
Total stockholders' (deficit) equity	289,068,000	(46,706,000)
Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity	298,675,000	129,164,000
Series A-1 Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred stock	0	12,574,000
Series A-2 Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred stock	0	19,476,000
Series A-3 Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred stock	0	33,288,000
Series B Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred stock	$ 0	$ 104,846,000

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Temporary Equity, Shares Authorized		49,624,190
Temporary Equity, Shares Issued		49,624,187
Temporary Equity, Shares Outstanding		49,624,187
Temporary Equity, Liquidation Preference		$ 160,970
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	500,000,000	72,731,000
Common stock issued (in shares)	39,377,222	4,237,290
Common Stock, Shares, Outstanding	39,377,222	4,237,290
Preferred stock, Par Value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	0
Preferred stock, shares issued	0	0
Preferred shares outstanding	0	0
Series A-1 Redeemable Convertible Preferred Stock
Temporary Equity, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized		13,970,000
Temporary Equity, Shares Issued		13,970,000
Temporary Equity, Shares Outstanding		13,970,000
Temporary Equity, Liquidation Preference		$ 13,970
Series A-2 Redeemable Convertible Preferred Stock
Temporary Equity, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized		13,750,000
Temporary Equity, Shares Issued		13,750,000
Temporary Equity, Shares Outstanding		13,750,000
Temporary Equity, Liquidation Preference		$ 22,000
Series A-3 Redeemable Convertible Preferred Stock
Temporary Equity, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized		7,812,501
Temporary Equity, Shares Issued		7,812,501
Temporary Equity, Shares Outstanding		7,812,501
Temporary Equity, Liquidation Preference		$ 20,000
Series B Redeemable Convertible Preferred Stock
Temporary Equity, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized		14,091,689
Temporary Equity, Shares Issued		14,091,686
Temporary Equity, Shares Outstanding		14,091,686
Temporary Equity, Liquidation Preference		$ 105,000

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 24,407	$ 15,748
General and administrative	13,301	3,256
Total operating expenses	37,708	19,004
Loss from operations	37,708	19,004
Other (income) expense, net:
Change in fair value of anti-dilution right liability	0	682
Change in fair value of preferred stock tranche liability	0	9,928
Other (income)	(2,553)	(5)
Total other (income) expense, net	(2,553)	10,605
Net loss	$ 35,155	$ 29,609
Net loss per share of common stock, basic	$ 2.62	$ 7.32
Net loss per share of common stock, diluted	$ 2.62	$ 7.32
Weighted-average common stock outstanding, basic	13,426,066	4,043,416
Weighted-average common stock outstanding, diluted	13,426,066	4,043,416

CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock Series A-1 Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Series A-2 Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Series A-3 Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Series B Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Series A-2 Second Tranche Series A-2 Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning balance at Dec. 31, 2020	$ (18,357)	$ 11,008	$ 7,691	$ 0	$ 0		$ 1	$ 274	$ (18,632)
Beginning balance, shares at Dec. 31, 2020		12,746,961	6,875,000	0	0		3,866,138
Issuance of redeemable convertible preferred stock		$ 1,566		$ 33,288	$ 104,846	$ 11,785
Issuance of redeemable convertible preferred stock, shares		1,223,039		7,812,501	14,091,686	6,875,000
Gain on extinguishment of Series A-2 redeemable convertible preferred stock tranche liability	750	$ 0	$ 0	$ 0	$ 0			750
Gain on extinguishment of Series A-2 redeemable convertible preferred stock tranche liability, shares		0	0	0	0		0
Vesting of restricted stock	0	$ 0	$ 0	$ 0	$ 0		$ 0	0	0
Vesting of restricted stock, shares		0	0	0	0		371,152
Stock-based compensation expense	510	$ 0	$ 0	$ 0	$ 0			510
Net loss	(29,609)	0	0	0	0				(29,609)
Ending balance at Dec. 31, 2021	(46,706)	$ 12,574	$ 19,476	$ 33,288	$ 104,846		$ 1	1,534	(48,241)
Ending balance, shares at Dec. 31, 2021		13,970,000	13,750,000	7,812,501	14,091,686		4,237,290
Vesting of restricted stock	0	$ 0	$ 0	$ 0	$ 0		$ 0	0	0
Vesting of restricted stock, shares		0	0	0	0		624,334
Stock-based compensation expense	4,751	$ 0	$ 0	$ 0	$ 0			4,751
Exercise of stock options	107	$ 0	$ 0	$ 0	$ 0			107
Exercise of stock options, shares		0	0	0	0		13,282
Conversion of convertible preferred stock into common stock upon closing of initial public offering	170,186	$ (12,574)	$ (19,476)	$ (33,288)	$ (104,846)		$ 2	170,184
Conversion of convertible preferred stock into common stock upon closing of initial public offering, shares		(13,970,000)	(13,750,000)	(7,812,501)	(14,091,686)		21,967,316
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $2.3M	195,885	$ 0	$ 0	$ 0	$ 0		$ 1	195,884
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $2.3M, shares		0	0	0	0		12,535,000
Net loss	(35,155)	$ 0	$ 0	$ 0	$ 0		$ 0	0	(35,155)
Ending balance at Dec. 31, 2022	$ 289,068	$ 0	$ 0	$ 0	$ 0		$ 4	$ 372,460	$ (83,396)
Ending balance, shares at Dec. 31, 2022		0	0	0	0		39,377,222

CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Issuance costs	$ 2,300
Series A-2 Redeemable Convertible Preferred Stock
Issuance costs		$ 40
Series A-3 Redeemable Convertible Preferred Stock
Issuance costs		40
Series B Redeemable Convertible Preferred Stock
Issuance costs		$ 154

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (35,155)	$ (29,609)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	4,751	510
Depreciation	1	0
Change in fair value of preferred stock tranche liability	0	9,928
Change in fair value of anti-dilution liability	0	682
Noncash operating lease expense	37	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(3,071)	(728)
Other assets	(1,037)	0
Accounts payable	290	1,216
Accrued expenses and other current liabilities	(708)	2,255
Changes in operating lease liabilities	(25)	0
Net cash used in operating activities	(34,917)	(15,746)
Cash flows from investing activities:
Purchase of property and equipment	(36)	0
Net cash used in investing activities	(36)	0
Cash flows from financing activities:
Proceeds from issuance of preferred stock, net of issuance costs	0	135,749
Proceeds from issuance of common stock in initial public offering, net of issuance costs and underwriting fees	198,178	0
Proceeds from the exercise of stock options	107	0
Payment of offering costs	(2,294)	0
Net cash provided by financing activities	195,991	135,749
Net increase in cash, cash equivalents and restricted cash	161,038	120,003
Cash, cash equivalents and restricted cash at beginning of period	128,280	8,277
Cash, cash equivalents and restricted cash at end of period	289,318	128,280
Supplemental disclosure of cash flows:
Right of use asset obtained in exchange for operating lease liability	$ 4,364	$ 0
Conversion of preferred stock into common stock	170,184	0
Preferred stock tranche liability established in connection with the issuance of redeemable convertible preferred stock	$ 0	$ 2,979
Issuance of redeemable convertible preferred stock in settlement of preferred stock tranche liability	0	17,149
Gain on extinguishment of preferred stock tranche liability record to additional paid in capital	0	750
Issuance of redeemable convertible preferred stock in settlement of anti-dilution right liability	$ 0	$ 1,566

Nature of the Business

12 Months Ended

Dec. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of the Business

1. Nature of the Business

Third Harmonic Bio, Inc., or the Company, is a biopharmaceutical company focused on advancing the next wave of medicine for the treatment of inflammatory disease, including dermal, respiratory, and gastrointestinal diseases.

The Company was incorporated in 2019 as a Delaware corporation, and we have two offices located in San Francisco, California and Cambridge, Massachusetts. In December 2021, the Company formed THB MS, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, which is classified as a Security Corporation in Massachusetts.

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, completion and success of clinical testing, development by competitors of new technological innovations, compliance with governmental regulations, dependence on key personnel and protection of proprietary technology and the ability to secure additional capital to fund operations. Development of a drug candidate requires extensive research and development and clinical testing prior to regulatory approval and commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

Initial public offering

On September 19, 2022, the Company closed its initial public offering, or the IPO, and issued 12,535,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,635,000 additional shares of common stock, at a public offering price of $17.00 per share. The Company received $198.2 million, net of underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2.3 million. Immediately prior to the closing of the IPO, all outstanding shares of redeemable convertible preferred stock converted into 21,967,316 shares of common stock (see Note 8). In connection with the closing of its IPO, on September 19, 2022, the Company amended its certificate of incorporation to authorize the issuance of up to 500,000,000 shares of $0.0001 par value common stock and 10,000,000 shares of $0.0001 par value preferred stock.

Reverse stock split

On September 7, 2022, the Company effected a 1-for-2.259 reverse stock split of the Company’s outstanding common stock. All common stock, stock options and per share information presented in the consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented. There was no change in the par value of the Company’s common stock. The ratio by which shares of preferred stock are convertible into shares of common stock was adjusted to reflect the effects of the reverse stock split.

Liquidity

In accordance with Accounting Standards Codification, or ASC, 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying consolidated financial statements were issued.

As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and staffing the Company, business planning, raising capital, establishing its intellectual property portfolio, acquiring or discovering product candidates, research and development activities for an oral KIT inhibitor and other compounds, establishing arrangements with third parties for the manufacture of its product candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future.

Since its inception, the Company has funded its operations primarily with proceeds from sales of shares of its redeemable convertible preferred stock and most recently with proceeds from the IPO. The Company has incurred recurring losses since its inception, including net losses of $29.6 million and $35.2 million for the years ended December 31, 2021 and 2022, respectively. As of December 31, 2022, the Company had an accumulated deficit of $83.4 million. To date the Company has not generated any revenues and expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash and cash equivalents of $288.9 million as of December 31, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these consolidated financial statements.

COVID-19 Pandemic

The global coronavirus disease 2019, or COVID-19, pandemic continues to evolve, and the Company will continue to monitor the ongoing COVID-19 pandemic. The extent of the impact of the ongoing COVID-19 pandemic on the Company’s business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on the Company’s contract development and manufacturing organizations, or CDMOs, contract research organizations, or CROs, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and key scientific and management personnel. The ultimate impact of the ongoing COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. The Company’s financial results for the year ended December 31, 2021 and 2022, were not significantly impacted by the ongoing COVID-19 pandemic, however, the Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition, operations, and business plans for 2023, including the timing and enrollment of patients in its planned clinical trials and other expected milestones of its future product candidates.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation and Consolidation

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and include the operations of Third Harmonic Bio, Inc. and its wholly-owned subsidiary. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and as amended by Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board, or FASB. All intercompany accounts, transactions, and balances have been eliminated in consolidation.

Use of Estimates

The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, and the valuations of common stock, preferred stock tranche liability, and anti-dilution right liability. The Company bases its estimates on historical experience when available, known trends and other market-specific data, or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

Segment Information

Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company’s focus is the research and development of the treatment of mast cell driven inflammatory diseases. The Company’s chief operating decision maker, its chief executive officer, manages the Company’s operations on a consolidated basis for the purpose of allocating resources.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include standard checking accounts and amounts held in money market funds. These accounts are guaranteed by the Federal Deposit Insurance Corporation, or FDIC, up to $250,000 per account per institution. At December 31, 2022, we held deposits in excess of FDIC insured limits.

Restricted Cash

As of December 31, 2022, the Company was required to maintain a separate cash balance of $0.3 million and $0.2 million in the form of a letter of credit, for the benefit of the landlord in connection with the Company's Prospect Street office space lease in Cambridge, Massachusetts, or the Prospect Street Lease, and the Company's Montgomery Street office space lease in San Francisco, California, or the Montgomery Street Lease, respectively, which are each classified as restricted cash (non-current) on the consolidated balance sheets (see Note 12).


	December 31, 2021		December 31, 2022
Cash and cash equivalents	$	128,280	$	288,877
Restricted cash		—		441
Cash, cash equivalents and restricted cash	$	128,280	$	289,318

Concentration of Credit Risk and Off-Balance Sheet Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short term marketable securities. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any losses related to its cash equivalents and marketable securities and management believes the Company is not exposed to significant risks of losses.

As of December 31, 2022, the Company held cash deposits at Silicon Valley Bank, or SVB, in excess of FDIC insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation, or FDIC, was appointed as receiver. No losses were incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the vast majority of the Company’s deposits were either owned directly by the Company or held in custody at a third-party financial institution. As of March 27, 2023, the Company has approximately $3.4 million on deposit with SVB and is currently evaluating its banking relationships in light of recent events.

The Company is dependent on third-party CDMO’s and CROs with whom it does business. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements of active pharmaceutical ingredients and formulated drugs in order to perform research and development activities in its programs. The Company also relies on a limited number of third-party CROs to perform research and development activities on its behalf. These programs could be adversely affected by significant interruption from these providers.

Fair Value Measurements

Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s preferred stock tranche liability and anti-dilution right liability were carried at fair value, determined according to Level 3 inputs in the fair value hierarchy described above.

An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.

Research and Development Expenses

Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation expense, clinical trial costs, contracted research services, research-related manufacturing, and other external costs.

The Company has entered into various research and development and other agreements with commercial firms, researchers, universities, and others for provisions of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, nonclinical and clinical development activities, and clinical trials as well as to manufacture clinical trial materials, and other costs.

Nonrefundable advance payments for goods and services to be received in the future for use in research and development activities are recorded as prepaid expenses and expenses as the related goods are delivered or the services are performed.

Accrued Research and Development Expenses

The Company has entered into various research and development contracts. The payments under these contracts are generally cancellable and are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes the progress of the research and development activities, including the phase or completion of events, invoices received and contracted costs. Significant judgements and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.

Patent Costs

All patent-related costs incurred in connection with filing and prosecuting patent applications such as direct application fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related costs are classified as general and administrative expenses within the Company’s consolidated statements of operations.

Property, Plant and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization, and comprise of furniture and equipment for use in the Company's office space, as well as leasehold improvements made by the Company to the leased office space. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which is generally five years for furniture and equipment and three years for computer equipment. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements. Depreciation and amortization begin at the time the asset is placed in service.

Leases

The Company adopted FASB ASC 842 with an effective date of January 1, 2020, using the modified retrospective transition approach which uses the effective date as the date of initial application. In accordance with ASC 842, the Company determines whether an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date, when control of the underlying asset is transferred from the lessor to the lessee, as operating or finance leases and records a right-of-use, or ROU, asset and a lease liability on the consolidated balance sheet for all leases with an initial lease term of greater than 12 months. The Company has elected to not recognize leases with a lease term of 12 months or less on the balance sheet.

The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. For leases of real estate, the Company combines the lease and associated non-lease components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.

Lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease if readily determinable. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the lease commencement date. ROU assets are further adjusted for initial direct costs, prepaid rent, or incentives received. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.

Redeemable Convertible Preferred Stock

The Company classified redeemable convertible preferred stock, or Preferred Stock, as temporary equity in the accompanying consolidated balance sheets due to terms that allowed for redemption of the shares upon certain events that are outside of the Company’s control. Costs incurred in connection with the issuance of redeemable convertible preferred stock, as well as the recognition of the preferred stock tranche liability, were recorded as a reduction of gross proceeds from issuance. The Company did not accrete the carrying values of the preferred stock to the redemption values since the occurrence of these events were not considered probable as of December 31, 2021. Immediately prior to the closing of the initial public offering on September 19, 2022, all outstanding shares of our redeemable convertible preferred stock were converted into common stock (see Note 7).

Preferred Stock Tranche Liability

The Company classified the preferred stock tranche liability for the future purchase, and option to purchase, preferred stock as a liability on its balance sheets as the preferred stock tranche liability was a freestanding financial instrument that would have required the Company to transfer equity instruments upon subsequent closings of the preferred stock financings. The preferred stock tranche liability was initially recorded at fair value upon the date of issuance and was subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred stock tranche liability were recognized as a component of other income and expense in the statements of operations. Changes in the fair value of the preferred stock tranche liability were recognized until the tranche liability was fulfilled or otherwise extinguished. As of December 31, 2021, the preferred stock tranche liability has been fulfilled or otherwise extinguished (see Note 7) in full.

Anti-Dilution Right Liability

The Company classified the anti-dilution right under its license agreement with Novartis International Pharmaceutical Ltd., or Novartis, as a derivative liability on its consolidated balance sheets as the anti-dilution right represented a freestanding financial instrument that may have required the Company to transfer equity instruments upon future equity closings. The anti-dilution right liability was initially recorded at fair value upon the date of issuance and was subsequently remeasured to fair value at each reporting date. The issuance date fair value of the anti-dilution right liability was recognized as a research and development expense upon entering into the agreement with Novartis. Changes in the fair value of the anti-dilution right liability were recognized as a component of other income and expense in the statements of operations. Changes in the fair value of the antidilution right liability were recognized until the anti-dilution right with Novartis was satisfied in the first quarter of 2021, in connection with the closing of the second tranche of the Series A-2 redeemable convertible preferred stock, or Series A-2 Preferred Stock, and the issuance and sale of the Series A-3 redeemable convertible preferred stock, or Series A-3 Preferred Stock. As of December 31, 2021, the anti-dilution liability was fulfilled (see Note 6).

Stock-Based Compensation

The Company accounts for all share-based payment awards granted to employees and non-employees as stock-based compensation expense at fair value, based on the date of the grant, and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company’s share-based payments include stock options and grants of restricted stock awards. For stock-based awards with service-based vesting conditions, the Company recognizes compensation expense using the straight-line method. For awards with both performance and service-based vesting conditions, the Company records expense using an accelerated attribution method, once the performance conditions are considered probable of being achieved, using management’s best estimates.

The fair value of each stock option is estimated on the grant date using the Black-Scholes option pricing model, which requires inputs based on certain subjective assumptions, including:

•

Fair Value of Common Stock—Prior to the Company's IPO, the Company determined that based on the stage of development and other relevant factors, it was most appropriate to prepare the common stock valuations using the option-pricing method, or OPM, which used a market approach to estimate our enterprise value. After the completion of the Company’s IPO, the Company will determine the fair value of the common stock based on the quoted market price of the common stock.

•

Expected Term—The expected term represents the period that the stock-based awards are expected to be outstanding. We use the simplified method to determine the expected term, which is based on the average of the time-to-vesting and the contractual life of the options.

•

Expected Volatility—Due to our limited operating history and lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.

•

Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the awards.

•

Dividend Yield—We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero.

Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.

The Company adopted ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, or ASU No. 2018-07, at inception of the 2019 Stock Incentive Plan, prior to the issuance of any stock option grants. The measurement date for non-employee awards is the date of grant. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis.

Stock-based compensation expense is classified in the accompanying consolidated statement of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients service payments are classified.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

Deferred tax assets are recognized to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (i) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

Interest and penalties are recognized related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December 31, 2021 and 2022, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.

Comprehensive Loss

Comprehensive loss includes net loss as well as other changes in stockholders’ deficit that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021 and 2022, there was no difference between net loss and comprehensive loss and accordingly a statement of comprehensive loss is not presented.

Net Income (Loss) Per Share

The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities, which included the Company’s redeemable convertible preferred stock, according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

The Company’s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders for years ended December 31, 2021, and 2022.

Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of diluted securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares. For the purpose of this calculation, unvested restricted common stock, outstanding stock options, and redeemable convertible preferred stock are considered potential dilutive common shares.

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Recently Adopted Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act, the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.

In December 2019, the FASB issued ASU No. 2019-12, or ASU-2019-12, Simplifying the Accounting for Income Tax, which contains several provisions that reduce financial statement complexity including removing the exception to the incremental approach for intra-period tax expense allocation when a company has a loss from continuing operations and income from other items not included in continuing operations. The Company adopted this accounting standard as of January 1, 2022 with no material impact on its consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

Management evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on the consolidated financial statements and related disclosures.

Fair Value Measurements

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis (in thousands):


			December 31, 2021
Description	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Observable Inputs (Level 3)
Money market funds	$	22,505	$	22,505	$	—	$	—
Total financial assets	$	22,505	$	22,505	$	—	$	—


			December 31, 2022
Description	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Observable Inputs (Level 3)
Money market funds	$	286,580	$	286,580	$	—	$	—
Total financial assets	$	286,580	$	286,580	$	—	$	—

As of December 31, 2021 and December 31, 2022, the Company had no financial liabilities that required fair value measurement. As of December 31, 2021 and December 31, 2022, the Company’s cash equivalents consisted of money market funds, classified as Level 1 financial assets, as these assets are valued using quoted market prices in active markets without any valuation adjustment.

During the year ended December 31, 2021 and year ended December 31, 2022 there were no transfers or reclassifications between fair value measurement levels of assets or liabilities. The carrying values of prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

4. Property, Plant and Equipment

Property, plant and equipment consisted of the following (in thousands):


	December 31, 2021		December 31, 2022
Construction in progress	$	—	$	16
Office furniture		—		—
Computer equipment		—		20
Lab equipment		—		—
Property, plant and equipment, gross		—		36
Less: Accumulated depreciation		—		(1	)
Property, plant and equipment, net	$	—	$	35

Depreciation expense was $1 for the year ended December 31, 2022, which has been recorded within general and administrative expenses.

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2022

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

5. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	December 31, 2021		December 31, 2022
Accrued research and development expenses	$	2,685	$	1,444
Professional fees		450		339
Employee compensation and related benefits		752		1,165
Other		2		233
Total accrued expenses and other current liabilities	$	3,889	$	3,181

Novartis License Agreement

12 Months Ended

Dec. 31, 2022

License Agreement [Abstract]

Novartis License Agreement

6. Novartis License Agreement

On June 28, 2019, the Company entered into a License Agreement, or the Novartis License Agreement, with Novartis Pharma AG, formerly known as Novartis International Pharmaceutical Ltd, or Novartis. Pursuant to the Novartis License Agreement, the Company has been granted an exclusive, worldwide, royalty-bearing, sublicensable license under specified patent rights and know-how related to two licensed compounds, to develop, make, use and sell certain products incorporating or comprising a licensed compound, including THB001, to certain intellectual property rights owned or controlled by Novartis, or the Licensed IP, to research, develop, make, use, sell, and commercialize products containing the Licensed IP.

Under the Novartis License Agreement, the Company is solely responsible for all research, development, regulatory and commercialization activities related to the Licensed IP. The Company is required to use commercially reasonable efforts to develop and seek regulatory approval for, and commercialize, at least one licensed product in each of the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.

In exchange for these rights, the Company made an upfront cash payment of $0.4 million and issued 3,449,808 shares of Series A-1 Preferred Stock with a fair value of $3.0 million to Novartis. Upon entering into the Novartis License Agreement in 2019, the total initial consideration of $3.4 million transferred to Novartis was charged to expenses as research and development expense. The Company determined that the Novartis License Agreement represented an asset acquisition as it did not meet the definition of a business. The Company recorded the initial consideration transferred to Novartis as research and development expense in the statement of operations because the acquired Licensed IP represented in-process research and development with no alternative future use.

In addition, under the Novartis License Agreement, an anti-dilution right was issued to Novartis, in which Novartis is entitled to receive shares of Series A-1 Preferred Stock, guaranteeing them a 15% ownership interest of the fully diluted capitalization of the Company. The Company was obligated to issue additional shares of Series A-1 Preferred Stock until the Company had (1) raised aggregate cumulative proceeds of $30.0 million from sales of equity securities since its inception; or (2) issued and sold any securities that generate proceeds in excess of $30.0 million. Additionally, the Company was not obligated to issue more than 6,383,142 shares of the Series A-1 Preferred Stock to Novartis under the anti-dilution right. The Company assessed the Novartis anti-dilution right and determined that the right (i) meets the definition of a freestanding financial instrument that is not indexed to the Company’s own stock and (ii) meets the definition of a derivative and does not qualify for equity classification. The initial fair value of the anti-dilution right liability of $1.0 million was recorded as research and development expense in July 2019, as part of the initial consideration in the license agreement. The Company remeasured the liability associated with the anti-dilution right at each reporting date and at each issuance of Series A-1 Preferred Stock under the anti-dilution right. Changes in the fair value were recorded as other income and expense in the statement of operations until the anti-dilution right was satisfied in February 2021 upon the Company raising aggregate cumulative proceeds of $30.0 million in sales of equity securities. As part of the anti-dilution right, the Company issued a total of 5,970,000 shares of Series A-1 Preferred Stock to Novartis. During the year ended December 31, 2021, the Company recorded an expense associated with changes in fair value of the anti-dilution right liability of $0.7 million. No expense was recognized during the year ended December 31, 2022 as the anti-dilution liability was satisfied in February 2021.

Under the Novartis License Agreement, the Company is obligated to make aggregate milestone payments of up to $231.7 million related to the achievement of specified development, commercialization, and sales milestones. The Company records the milestone payments as research and development expenses when the milestones occur and consideration is paid or becomes payable. As of December 31, 2022, the Company has made two development milestone payments under the Novartis Agreement totaling $1.0 million, of which $0.4 million was achieved and paid in 2019, and $0.6 million was achieved and paid in 2020, which have been recorded as research and development expense. No other milestones have occurred or have been paid under the Novartis License Agreement.

As part of the Novartis License Agreement, the Company also agreed to pay tiered royalties based on future net sales of all products licensed under the agreement, of which the royalty percentage ranged within the single digits.

Redeemable Convertible Preferred Stock

12 Months Ended

Dec. 31, 2022

Temporary Equity Disclosure [Abstract]

Redeemable Convertible Preferred Stock

7. Redeemable Convertible Preferred Stock

As of December 31, 2021, the redeemable convertible preferred stock consisted of the following (in thousands, except share amounts):


	Preferred Stock Authorized		Preferred Stock Issued and Outstanding		Carrying Value		Liquidation Value		Common Stock Issuable Upon Conversion
Series A-1 Preferred Stock		13,970,000		13,970,000	$	12,574	$	13,970		6,184,150
Series A-2 Preferred Stock		13,750,000		13,750,000		19,476		22,000		6,086,762
Series A-3 Preferred Stock		7,812,501		7,812,501		33,288		20,000		3,458,386
Series B Preferred Stock		14,091,689		14,091,686		104,846		105,000		6,238,018
Total		49,624,190		49,624,187	$	170,184	$	160,970		21,967,316

Immediately prior to the closing of the initial public offering on September 19, 2022, all outstanding shares of our redeemable convertible preferred stock were converted into 21,967,316 shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. Accordingly, there were no shares of redeemable convertible preferred stock outstanding as of December 31, 2022.

Stockholder's Equity (Deficit)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Stockholder's Equity (Deficit)

8. Stockholder's Equity (Deficit)

Common stock

As of December 31, 2021 and December 31, 2022, the Company’s Amended and Restated Certificate of Incorporation authorized the Company to issue 72,731,000 and 500,000,000 shares of common stock, with a par value of $0.0001, respectively. The voting, dividend and liquidation rights of the holders of the Company’s common stock were subject to and qualified by the rights, preferences and privileges of the holders of the redeemable convertible preferred stock.

The holders of the common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. There are not cumulative voting rights for the election of directors in the restated certificate of incorporation, which means that holders of a majority of the shares of the common stock will be able to elect all of the directors. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, or the Board, if any, subject to the preferential dividend rights of redeemable convertible preferred stock. Through December 31, 2022, no cash dividends had been declared or paid.

On September 19, 2022, the Company completed its IPO, at which time the Company issued 12,535,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,635,000 additional shares of common stock, at a public offering price of $17.00 per share. The Company received $198.2 million, net of underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2.3 million. Upon the closing of the IPO, all outstanding shares of redeemable convertible preferred stock converted into 21,967,316 shares of common stock (see Note 6). As of December 31, 2021 and December 31, 2022, there were 4,237,290 and 39,377,222 shares of common stock issued and outstanding, respectively.

The following shares of common stock were reserved for issuance as follows:


	December 31, 2021		December 31, 2022
Conversion of outstanding shares of preferred stock		21,967,316		—
Options to purchase common stock		394,254		3,644,500
Unvested restricted common stock		1,907,102		964,992
Remaining shares reserved for future issuance		2,065,764		3,801,282
Total		26,334,436		8,410,774

Undesignated preferred stock

As of December 31, 2022, the Company’s Amended and Restated Certificate of Incorporation authorized the Company to issue up to 10,000,000 shares of undesignated preferred stock, par value $0.0001 per share. There were no undesignated preferred shares issued or outstanding as of December 31, 2022.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Stock-Based Compensation

12 Months Ended

Dec. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

2019 Stock Incentive Plan

The Company's 2019 Stock Incentive Plan, or the 2019 Plan, provided for the Company to grant incentive stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. The 2019 Plan was administered by the Board or, at the discretion of the Board, by a committee delegated by Board. The exercise prices, vesting and other restrictions were determined at the discretion of the Board, or its committee if so delegated. The Company’s Board valued the Company’s common stock, taking into consideration its most recently available valuation of common stock performed by third party valuation specialists as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant.

The total number of shares of common stock that could have been issued under the 2019 Plan was 5,317,559 shares, of which 283,808 shares remained available for grant on September 19, 2022, the date that the Company's 2022 Equity Incentive Plan, or the 2022 Plan, became effective. Upon the effectiveness of the 2022 Plan, the 283,808 remaining shares available under the 2019 Plan were transferred and became available for issuance under the 2022 Plan. Shares of common stock underlying outstanding awards under the 2019 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added to the shares of common stock available for issuance under the 2022 Plan.

2022 Plan

The 2022 Plan was approved by the Board and stockholders in August 2022. The 2022 Plan became effective on September 14, 2022 and replaced the Company's 2019 Plan on that date. The 2022 Plan authorizes the award of incentive stock options, or ISOs, non-qualified stock options, or NQSOs, Restricted Stock Awards, or RSAs, Stock Appreciation Rights, or SARs, Restricted Stock Units, or RSUs, performance awards and stock bonus awards. Pursuant to the 2022 Plan, ISOs may be granted only to employees.

The number of shares initially reserved for issuance under the 2022 Plan is 4,710,545 shares of common stock, which includes the 283,808 shares transferred from the 2019 Plan, and shall automatically increase on January 1 of each of 2023 through 2032 by the number of shares equal of the lesser of 5% of the aggregate number of shares of all classes of the common stock, plus the total number of shares of common stock issuable upon conversion of any preferred stock (if any) or exercise of any pre-funded warrants, as issued and outstanding as of the immediately preceding December 31, or a number as may be determined by the Board.

The 2022 Plan is administered by the Board or, at the discretion of the Board, by a committee of the Board. The exercise prices, vesting and other restrictions are determined at the discretion of the Board, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of stock option may not be greater than ten years.

Shares that are expired terminated, surrendered or cancelled under the 2022 Plan without having been fully exercised will be available for future awards.

Stock Options

The assumptions that the Company used to determine the grant-date fair value of stock options awarded to employees, were as follows for the year ended December 31, 2021 and 2022:


	Year Ended December 31,
	2021		2022
Expected term (in years)	6.06-6.53		5.19-6.53
Expected volatility	82.4 - 84.2%		72.8-83.5%
Risk-free interest rate	0.87-1.20%		1.70-4.21%
Expected dividend yield		—		—
Fair value of common stock	$	1.90	$4.30-18.40

The following table summarizes the Company’s stock option activity since December 31, 2021:


	Number of Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2021		394,254		$	0.85		9.08	$	3,294
Granted		3,448,476			11.41
Exercised		(13,283	)		7.92
Forfeited or cancelled		(184,947	)		8.19
Outstanding as of December 31, 2022		3,644,500			10.45		9.51		1,283
Options vested and exercisable as of December 31, 2022		173,529			6.82		8.93		581
Options unvested as of December 31, 2022		3,470,971			10.70		9.57		769

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock.

The weighted-average grant-date fair value per share of stock options granted during the year ended December 31, 2022 was $8.27. As of December 31, 2022, there was $25.3 million of unrecognized stock-based compensation expense related to unvested stock options, to be recognized over a weighted-average period of 3.70 years.

The total fair value of options vested during the year ended December 31, 2022 was $1.9 million.

Included within the total stock options outstanding are 115,580 stock options to purchase common stock which have performance-based vesting criteria and were granted to certain employees, officers and consultants of the Company on various dates during the years ended December 31, 2020 and 2021, collectively, the Performance Stock Options. Vesting of 37,133 of the Performance Stock Options was contingent on the closing of the Series A-2 Second Tranche, which occurred on February 24, 2021, and vesting of the remaining 97,938 Performance Stock Options was contingent on the closing of the Series A-3 Second Tranche, which occurred on November 15, 2021. The vesting commencement date of the Performance Stock Options was the date in which the performance condition is met, and vesting occurs based on the accelerated attribution method over four years from the vesting commencement date. The Company began to recognize expense associated with the Performance Stock Options on the date in which each respective performance criteria was met and recognized total stock-based compensation expense associated with the Performance Stock Options of less than $0.1 million for the year ended December 31, 2021 and $0.1 million for the year ended December 31, 2022. No expense associated with the Performance Stock Options was recognized prior to the year ended December 31, 2021.

Restricted Common Stock Awards

The Company has granted restricted common stock awards with service and performance and service based vesting conditions to employees of the Company. Unvested shares of restricted common stock may not be sold or transferred by the holder, except for transfers for estate planning purposes in which the transferee agrees to remain bound by all restrictions set forth in the original common stock purchase agreement. These restrictions lapse over the vesting term of each award, which is typically four years. The purchase price of each share of restricted common stock was $0.0001 per share.

On August 9, 2021, the Company’s chief executive office, or CEO, purchased 1,218,836 shares of common stock at a purchase price of $1.44 per share, under the terms of a restricted common stock award granted under the 2019 Plan. These shares were purchased in exchange for a promissory note, or the Promissory Note, of $1.8 million. The shares granted include both service and performance-based vesting criteria and accrued at an interest rate of 0.76% per annum, compounded annually and were accounted for as restricted stock.

On August 22, 2022, the Company forgave the entire promissory note, including principal and accrued and unpaid interest. As a result this is considered a modification to the original awards, and the Company recognized the grant date fair value plus any incremental fair value due to the modification. The incremental cost was measured as the difference between the fair value of the award at modification date and the fair value of the original award immediately prior to modification. As a result of accounting for the modification, the Company recorded an incremental stock based compensation charge of $1.0 million, which will be recognized over the remaining requisite service period of the award from the date of the modification.

The CEO was paid a one-time special bonus of $1.9 million to offset the CEO’s tax liability as a result of the forgiveness of the promissory note, or the Tax Payment, which is subject to a three-year vesting schedule with six-month cliffs. The Company is allowed to claw-back the unvested portion of the Tax Payment in the event that the CEO’s employment is terminated before the end of the three-year vesting period, provided that the CEO’s employment is terminated by the Company other than for cause, or if the CEO resigns for a good reason (a) within 12 months following a change of control, or (b) within 3 months preceding a change in control but as to only if the separation occurs after a potential change in control. In the event the CEO’s employment is terminated, the unvested portion of the Tax Payment will accelerate and will not be subject to the claw back provision. The clawback provision will be accounted for if and when the CEO leaves under the relevant circumstances and the payment amount will be capitalized and recognized over the related service period as G&A employee salary expense.

A summary of the activity of the restricted common stock since December 31, 2021:


	Number of Shares			Weighted-Average Grant Date Fair Value Per Share
Unvested at December 31, 2021		1,907,102		$	1.17
Granted		—			—
Vested		(624,334	)		1.33
Cancelled or forfeited		(317,776	)		0.71
Unvested at December 31, 2022		964,992		$	0.59

The weighted-average grant-date fair value per share of restricted common stock awards granted during the year ended December 31, 2022 was zero as no shares were granted in the period. The aggregate fair value of restricted stock awards that vested during the year ended December 31, 2022 was $0.7 million. Stock-based compensation expense recognized for the restricted stock granted was $1.1 million for the year ended December 31, 2022. As of December 31, 2022, there was unrecognized expense of $1.2 million related to the restricted stock, which is expected to be recognized over a weighted-average period of 2.29 years.

Stock-Based Compensation Expense

Stock-based compensation expense included in the Company’s consolidated statements of operations was as follows (in thousands):


	Year Ended December 31,
	2021		2022
Research and development		224		1,650
General and administrative		286		3,101
Total stock-based compensation expense		510		4,751

Income Taxes

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

10. Income Taxes

Income (loss) before provision for income taxes consisted of the following (in thousands):


	Year ended December 31,
	2021			2022
Domestic	$	(29,609	)	$	(35,155	)
Foreign		—			—
Loss before provision for income taxes	$	(29,609	)	$	(35,155	)

A reconciliation of the Company's statutory income tax rate to the Company's effective income tax rate is as follows:


	Year ended December 31,
	2021			2022
Income at US statutory rate		21.00	%		21.00	%
State taxes, net of federal benefit		3.43	%		3.60	%
Change in tranche liability		-7.04	%		0.00	%
Non-deductible Compensation		-0.21	%		-3.31	%
Tax credits		1.03	%		0.50	%
Valuation allowance		-18.21	%		-21.78	%
Other		0.00	%		-0.01	%
		0.00	%		0.00	%

The net deferred income tax asset balance related to the following (in thousands):


	Year ended December 31,
	2021			2022
Net operating loss carryforwards	$	7,935		$	10,336
Research and development credits		774			1,006
Intangibles		1,613			1,422
Capitalized research and development		—			5,433
Right of use liabilities		—			1,087
Stock-based compensation		—			211
Accrued expenses & other		252			274
Total deferred tax assets		10,574			19,769
Right of use assets		—			(1,084	)
Deferred compensation		—			(445	)
Other		—			—
Total deferred tax liabilities		—			(1,529	)
Net Deferred Tax assets		10,574			18,240
Valuation allowance		(10,574	)		(18,240	)
Deferred Tax Assets, Net of Valuation Allowance	$	—		$	—

As of December 31, 2021 and 2022, the Company had a federal net operating loss carryforward of $29.8 million and $38.9 million, respectively, which can be carried forward indefinitely. As of December 31, 2021 and 2022, the Company has state NOL carryforwards of $26.7 million and $34.1 million, respectively. The state net operating loss carryforwards begin to expire in 2039.

As of December 31, 2022, the Company also has federal and state tax credits of $0.8 million and $0.2 million, which begin to expire in 2039 and 2039, respectively.

The Tax Cuts and Jobs Act contained a provision which requires the capitalization of Section 174 costs incurred in years beginning on or after January 1, 2022. Section 174 costs are expenditures which represent research and development costs that are incident to the development or improvement of a product, process, formula, invention, computer software, or technique. This provision changes the treatment of Section 174 costs such that the expenditures are no longer allowed as an immediate deduction but rather must be capitalized and amortized. The Company has included the impact of this provision, which results in a deferred tax asset of approximately $5.4 million as of December 31, 2022.

Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December 31, 2021 and 2022, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full valuation allowance as of December 31, 2021 and 2022.

Under Internal Revenue Code Section 382, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. The Company has not completed a study to assess whether an “ownership change” has occurred or whether there have been multiple ownership changes since we became a “loss corporation” as defined in Section 382. Future changes in the Company's stock ownership, which may be outside of the Company's control, may trigger an “ownership change.” In addition, future equity offerings or acquisitions that have equity as a component of the purchase price could result in an “ownership change.” If an “ownership change” has occurred or does occur in the future, utilization of the NOL carryforwards or other tax attributes may be limited, which could potentially result in increased future tax liability to the Company.

The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which we operate or do business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.

The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company's current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2021 and 2022, the Company has not recorded any uncertain tax positions in our financial statements.

The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December 31, 2021 and 2022, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.

The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company’s tax years are still open under statute from December 31, 2019, to the present. The resolution of tax matters is not expected to have a material effect on the Company’s consolidated financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Net Loss Per Share

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Net Loss Per Share

11. Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share amounts):


	Year Ended December 31,
	2021		2022
Numerator:
Net loss	$	29,609	$	35,155
Net loss attributable to common stockholders, basic and diluted	$	29,609	$	35,155
Denominator:
Weighted-average number of common shares used in net loss per share, basic and diluted		4,043,416		13,426,066
Net loss per share of common stock, basic and diluted	$	7.32	$	2.62

The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders during the year ended December 31, 2021 and 2022 because including them would have had an anti-dilutive effect:


	Year Ended December 31,
	2021		2022
Redeemable convertible preferred stock		21,967,316		—
Options to purchase common stock		394,254		3,644,500
Unvested restricted stock		1,907,102		964,992
Total		24,268,672		4,609,492

Leases

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Leases

12. Leases

Operating Leases for Office Space

In October 2022, the Company entered into an office space lease approximating 10,356 of rentable square feet, located at 130 Prospect Street in Cambridge, Massachusetts. The lease commenced on December 1, 2022 when the Company took occupancy of the space, and has an initial lease term of 63 months, expiring on February 29, 2028 with no renewal options.

Also in October 2022, the Company entered into an office space lease approximating 4,703 of rentable square feet located at 1700 Montgomery Street in San Francisco, California. The lease commenced on December 20, 2022 when the Company took occupancy of the space, and has an initial lease term of 63 months, expiring on February 20, 2028 with no renewal options.

The Company also leased various office suites on a month-to month basis from Atlas Venture Life Science Advisors, or Atlas, and other third parties during the years ended December 31, 2021 and 2022. As the Company elected to not recognize leases with a lease term of 12 months or less on the balance sheet, no operating lease right of use assets and liabilities were recognized.

During the year ended December 31, 2021 and 2022, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:


	December 31, 2021		December 31, 2022
Lease Cost:	$	—	$	—
Operating lease cost		—		75
Variable operating lease cost		—		—
Short-term operating lease cost		97		195
Total operating lease cost	$	97	$	270

The following table summarizes information related to the measurement of the Company's operating leases for the years ended December 31, 2021 and 2022:


	December 31, 2021		December 31, 2022
Weighted-average remaining lease term		—		5.20
Weighted-average discount rate		—		10.5	%
Cash paid for amounts included in the measurement of operating lease liabilities	$	—	$	—

Maturities of operating lease liabilities at December 31, 2022 are as follows (in thousands):


2023	$	826
2024		1,116
2025		1,145
2026		1,176
Thereafter		1,445
Total lease payments		5,708
Less: interest		(1,369	)
Total lease liability	$	4,339

Commitments and Contingencies

12 Months Ended

Dec. 31, 2022

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

13. Commitments and Contingencies

Legal Proceedings

From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of December 31, 2021 and 2022, there were no litigation matters which would have a material impact on the Company’s financial results.

Related Party Transactions

12 Months Ended

Dec. 31, 2022

Related Party Transactions

14. Related Party Transactions

Entities Affiliated with Atlas Venture Fund XI, L.P.

Entities affiliated with Atlas Venture Fund XI, L.P. are a significant beneficial owner of the Company, holding more than 5% of the total outstanding stock of the Company, as of December 31, 2021 and 2022. The Company leased various office space from Atlas for use in its daily operations through September 2022.

During the year ended December 31, 2021 and 2022, the Company made payments of $0.2 million and $0.1 million, respectively associated with the lease agreements with Atlas, which was recorded within the general and administrative expense.

Novartis

Novartis is a significant beneficial owner of the Company, holding more than 5% of the total outstanding stock of the Company, as of December 31, 2021 and December 31, 2022. The Company has an in-license agreement with Novartis, which required the Company to make an upfront payment and issue shares of Series A-1 Preferred Stock to Novartis, and further includes future milestone payments upon the occurrence of certain events and royalty payments upon future sales. Refer to Note 6.

CEO Promissory Note

On August 9, 2021, the Company entered into the Promissory Note with the CEO for an amount of $1.8 million, which was used to allow the CEO to purchase 1,218,836 shares of common stock granted in the form of a restricted stock award under the 2019 Plan. The Promissory Note had a stated interest rate of 0.76%, which was compounded annually. The entire Promissory Note, including principal and accrued and unpaid interest, was forgiven on August 22, 2022. The Company has paid the CEO a one-time special bonus of $1.9 million, which was paid to offset the CEO's tax liability as a result of the forgiveness of the Promissory Note. This is subject to a three-year vesting schedule with six-month cliffs, as well as continued employment with the company on the relevant vesting dates. Refer to Note 15 Employee Benefit Plans.

Employee Benefit Plans

12 Months Ended

Dec. 31, 2022

Compensation And Retirement Disclosure [Abstract]

Employee Benefit Plans

15. Employee Benefit Plans

Effective January 1, 2019, the Company adopted a 401(k) Plan for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. Since inception of the plan and through the year ended December 31, 2022 the Company has not made any contributions to the 401(k) Plan.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Subsequent Events

12 Months Ended

Dec. 31, 2022

Subsequent Events [Abstract]

Subsequent Events

16. Subsequent Events

On March 6, 2023, the Board of Directors of the Company approved the reduction in exercise price of certain options that had been granted under the 2019 Plan and the 2022 Plan, that have an exercise price greater than or equal to $8.61 per share, which were each repriced at an exercise price of $4.20. There were no changes in the vesting schedule or maturity term of the options. The Company expects to record the impact of the option repricing in the quarter ending March 31, 2023.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Basis of Presentation and Consolidation

Use of Estimates

Segment Information

Cash and Cash Equivalents

Restricted Cash


	December 31, 2021		December 31, 2022
Cash and cash equivalents	$	128,280	$	288,877
Restricted cash		—		441
Cash, cash equivalents and restricted cash	$	128,280	$	289,318

Concentration of Credit Risk and Off-Balance Sheet Risk

Fair Value Measurements

Level 1—Quoted prices in active markets for identical assets or liabilities.

Research and Development Expenses

Accrued Research and Development Expenses

Patent Costs

Property, Plant and Equipment

Leases

Redeemable Convertible Preferred Stock

Preferred Stock Tranche Liability

Anti-Dilution Right Liability

Stock-Based Compensation

The fair value of each stock option is estimated on the grant date using the Black-Scholes option pricing model, which requires inputs based on certain subjective assumptions, including:

•

Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the awards.

•

Dividend Yield—We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero.

Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.

Income Taxes

Comprehensive Loss

Net Income (Loss) Per Share

Emerging Growth Company Status

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Cash and Cash Equivalents [Abstract]

Schedule of Cash And Cash Equivalents And Restricted Cash


	December 31, 2021		December 31, 2022
Cash and cash equivalents	$	128,280	$	288,877
Restricted cash		—		441
Cash, cash equivalents and restricted cash	$	128,280	$	289,318

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of Financial Assets Measured at Fair Value

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis (in thousands):


			December 31, 2021
Description	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Observable Inputs (Level 3)
Money market funds	$	22,505	$	22,505	$	—	$	—
Total financial assets	$	22,505	$	22,505	$	—	$	—


			December 31, 2022
Description	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Observable Inputs (Level 3)
Money market funds	$	286,580	$	286,580	$	—	$	—
Total financial assets	$	286,580	$	286,580	$	—	$	—

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment consisted of the following (in thousands):


	December 31, 2021		December 31, 2022
Construction in progress	$	—	$	16
Office furniture		—		—
Computer equipment		—		20
Lab equipment		—		—
Property, plant and equipment, gross		—		36
Less: Accumulated depreciation		—		(1	)
Property, plant and equipment, net	$	—	$	35

Depreciation expense was $1 for the year ended December 31, 2022, which has been recorded within general and administrative expenses.

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2022

Payables And Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	December 31, 2021		December 31, 2022
Accrued research and development expenses	$	2,685	$	1,444
Professional fees		450		339
Employee compensation and related benefits		752		1,165
Other		2		233
Total accrued expenses and other current liabilities	$	3,889	$	3,181

Redeemable Convertible Preferred Stock (Tables)

12 Months Ended

Dec. 31, 2022

Temporary Equity Disclosure [Abstract]

Summary of Redeemable Convertible Preferred Stock

As of December 31, 2021, the redeemable convertible preferred stock consisted of the following (in thousands, except share amounts):


	Preferred Stock Authorized		Preferred Stock Issued and Outstanding		Carrying Value		Liquidation Value		Common Stock Issuable Upon Conversion
Series A-1 Preferred Stock		13,970,000		13,970,000	$	12,574	$	13,970		6,184,150
Series A-2 Preferred Stock		13,750,000		13,750,000		19,476		22,000		6,086,762
Series A-3 Preferred Stock		7,812,501		7,812,501		33,288		20,000		3,458,386
Series B Preferred Stock		14,091,689		14,091,686		104,846		105,000		6,238,018
Total		49,624,190		49,624,187	$	170,184	$	160,970		21,967,316

Stockholder's Equity (Deficit) (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Schedule of Common Stock Reserved for Issuance

The following shares of common stock were reserved for issuance as follows:


	December 31, 2021		December 31, 2022
Conversion of outstanding shares of preferred stock		21,967,316		—
Options to purchase common stock		394,254		3,644,500
Unvested restricted common stock		1,907,102		964,992
Remaining shares reserved for future issuance		2,065,764		3,801,282
Total		26,334,436		8,410,774

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Options Valuation Assumptions

The assumptions that the Company used to determine the grant-date fair value of stock options awarded to employees, were as follows for the year ended December 31, 2021 and 2022:


	Year Ended December 31,
	2021		2022
Expected term (in years)	6.06-6.53		5.19-6.53
Expected volatility	82.4 - 84.2%		72.8-83.5%
Risk-free interest rate	0.87-1.20%		1.70-4.21%
Expected dividend yield		—		—
Fair value of common stock	$	1.90	$4.30-18.40

Summary of Stock Option Activity

The following table summarizes the Company’s stock option activity since December 31, 2021:


	Number of Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2021		394,254		$	0.85		9.08	$	3,294
Granted		3,448,476			11.41
Exercised		(13,283	)		7.92
Forfeited or cancelled		(184,947	)		8.19
Outstanding as of December 31, 2022		3,644,500			10.45		9.51		1,283
Options vested and exercisable as of December 31, 2022		173,529			6.82		8.93		581
Options unvested as of December 31, 2022		3,470,971			10.70		9.57		769

Summary of Restricted Common Stock Activity

A summary of the activity of the restricted common stock since December 31, 2021:


	Number of Shares			Weighted-Average Grant Date Fair Value Per Share
Unvested at December 31, 2021		1,907,102		$	1.17
Granted		—			—
Vested		(624,334	)		1.33
Cancelled or forfeited		(317,776	)		0.71
Unvested at December 31, 2022		964,992		$	0.59

Summary of Stock-Based Compensation Expense

Stock-based compensation expense included in the Company’s consolidated statements of operations was as follows (in thousands):


	Year Ended December 31,
	2021		2022
Research and development		224		1,650
General and administrative		286		3,101
Total stock-based compensation expense		510		4,751

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income (Loss) before Provision for Income Taxes

Income (loss) before provision for income taxes consisted of the following (in thousands):


	Year ended December 31,
	2021			2022
Domestic	$	(29,609	)	$	(35,155	)
Foreign		—			—
Loss before provision for income taxes	$	(29,609	)	$	(35,155	)

Reconciliation of Company's Statutory Income Tax Rate and Effective Income Tax Rate

A reconciliation of the Company's statutory income tax rate to the Company's effective income tax rate is as follows:


	Year ended December 31,
	2021			2022
Income at US statutory rate		21.00	%		21.00	%
State taxes, net of federal benefit		3.43	%		3.60	%
Change in tranche liability		-7.04	%		0.00	%
Non-deductible Compensation		-0.21	%		-3.31	%
Tax credits		1.03	%		0.50	%
Valuation allowance		-18.21	%		-21.78	%
Other		0.00	%		-0.01	%
		0.00	%		0.00	%

The net deferred income tax asset bal

Summary of Net Deferred Income Tax Asset Balance

The net deferred income tax asset balance related to the following (in thousands):


	Year ended December 31,
	2021			2022
Net operating loss carryforwards	$	7,935		$	10,336
Research and development credits		774			1,006
Intangibles		1,613			1,422
Capitalized research and development		—			5,433
Right of use liabilities		—			1,087
Stock-based compensation		—			211
Accrued expenses & other		252			274
Total deferred tax assets		10,574			19,769
Right of use assets		—			(1,084	)
Deferred compensation		—			(445	)
Other		—			—
Total deferred tax liabilities		—			(1,529	)
Net Deferred Tax assets		10,574			18,240
Valuation allowance		(10,574	)		(18,240	)
Deferred Tax Assets, Net of Valuation Allowance	$	—		$	—

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share amounts):


	Year Ended December 31,
	2021		2022
Numerator:
Net loss	$	29,609	$	35,155
Net loss attributable to common stockholders, basic and diluted	$	29,609	$	35,155
Denominator:
Weighted-average number of common shares used in net loss per share, basic and diluted		4,043,416		13,426,066
Net loss per share of common stock, basic and diluted	$	7.32	$	2.62

Schedule of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-dilutive Effect


	Year Ended December 31,
	2021		2022
Redeemable convertible preferred stock		21,967,316		—
Options to purchase common stock		394,254		3,644,500
Unvested restricted stock		1,907,102		964,992
Total		24,268,672		4,609,492

Leases (Tables)

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Components of Operating Lease Cost


	December 31, 2021		December 31, 2022
Lease Cost:	$	—	$	—
Operating lease cost		—		75
Variable operating lease cost		—		—
Short-term operating lease cost		97		195
Total operating lease cost	$	97	$	270

Summary of Information Related to Measurement of Operating Leases

The following table summarizes information related to the measurement of the Company's operating leases for the years ended December 31, 2021 and 2022:


	December 31, 2021		December 31, 2022
Weighted-average remaining lease term		—		5.20
Weighted-average discount rate		—		10.5	%
Cash paid for amounts included in the measurement of operating lease liabilities	$	—	$	—

Maturities of operating lease liabilities at

Maturities of Operating Lease Liabilities

Maturities of operating lease liabilities at December 31, 2022 are as follows (in thousands):


2023	$	826
2024		1,116
2025		1,145
2026		1,176
Thereafter		1,445
Total lease payments		5,708
Less: interest		(1,369	)
Total lease liability	$	4,339

Nature of the Business - Additional Information (Detail) $ / shares in Units, $ in Thousands			12 Months Ended
	Sep. 19, 2022 USD ($) $ / shares shares	Sep. 07, 2022	Dec. 31, 2022 USD ($) Office $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of offices \| Office			2
Proceeds from initial public offering \| $			$ 198,178	$ 0
Offering costs payable \| $			$ 2,294	$ 0
Conversion of convertible preferred stock into common stock				21,967,316
Number of shares authorized for issuance			500,000,000	72,731,000
Par value of common stock \| $ / shares			$ 0.0001	$ 0.0001
Undesignated preferred stock, authorized			10,000,000	0
Preferred stock, Par Value \| $ / shares			$ 0.0001	$ 0.0001
Description of reverse stock split			Company effected a 1-for-2.259 reverse stock split of the Company’s outstanding common stock
Reverse stock spilt conversion ratio		0.44267375
Net loss \| $			$ (35,155)	$ (29,609)
Accumulated deficit \| $			83,396	48,241
Cash and cash equivalents \| $			$ 288,877	128,280
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Undesignated preferred stock, authorized			10,000,000
IPO
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial public offering, Shares	12,535,000
Public offering price \| $ / shares	$ 17.00
Proceeds from initial public offering \| $	$ 198,200
Offering costs payable \| $	$ 2,300
Conversion of convertible preferred stock into common stock	21,967,316
Number of shares authorized for issuance	500,000,000
Par value of common stock \| $ / shares	$ 0.0001
Undesignated preferred stock, authorized	10,000,000
Preferred stock, Par Value \| $ / shares	$ 0.0001
Net loss \| $			$ (35,200)	$ (29,600)
Underwrites Option \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial public offering, Shares	1,635,000

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 27, 2023	Dec. 31, 2021
Summary of Significant Accounting Policies [Line Items]
Restricted cash	$ 441,000		$ 0
Accrued interest or penalties on unrecognized tax benefits	0		$ 0
Maximum
Summary of Significant Accounting Policies [Line Items]
Cash and cash equivalents guaranteed by FDIC	250,000,000
Letter of Credit \| Prospect Street Lease
Summary of Significant Accounting Policies [Line Items]
Restricted cash	$ 300,000
Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Restricted cash
Letter of Credit \| Montgomery Street Lease
Summary of Significant Accounting Policies [Line Items]
Restricted cash	$ 200,000
Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Restricted cash
Furniture and Equipment
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	5 years
Computer Equipment
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	3 years
Silicon Valley Bank
Summary of Significant Accounting Policies [Line Items]
Gain (losses) incurred on deposits held	$ 0
Subsequent Events \| Silicon Valley Bank
Summary of Significant Accounting Policies [Line Items]
Cash deposits currently evaluating banking relationships		$ 3,400,000

Summary of Significant Accounting Policies - Schedule of Cash And Cash Equivalents And Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 288,877	$ 128,280
Restricted cash	441	0
Cash, cash equivalents and restricted cash	$ 289,318	$ 128,280

Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 286,580	$ 22,505
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	286,580	22,505
Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	0	0
Significant Other Observable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	0	0
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	286,580	22,505
Money Market Funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	286,580	22,505
Money Market Funds \| Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	0	0
Money Market Funds \| Significant Other Observable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 0	$ 0

Fair Value Measurements - Additional Information (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Line Items]
Transfers or reclassifications between fair value measurement levels of assets	$ 0	$ 0
Transfers or reclassifications between fair value measurement levels of liabilities	0	0
Cash and Cash Equivalents
Fair Value Disclosures [Line Items]
Fair value measurement of financial liabilities	$ 0	$ 0

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 36	$ 0
Less: Accumulated depreciation	(1)	0
Property, plant and equipment, net	35	0
Construction in Progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	16	0
Office furniture
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	0	0
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	20	0
Lab equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 0	$ 0

Property, Plant and Equipment - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 1	$ 0
General and Administrative Expenses
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 1

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Accrued research and development expenses	$ 1,444	$ 2,685
Professional fees	339	450
Employee compensation and related benefits	1,165	752
Other	233	2
Total accrued expenses and other current liabilities	$ 3,181	$ 3,889

Novartis License Agreement - Additional Information (Details)			12 Months Ended
	Feb. 28, 2021 USD ($)	Jun. 28, 2019 USD ($) License shares	Dec. 31, 2022 USD ($) License shares	Dec. 31, 2021 USD ($) shares	Feb. 24, 2021 shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
License Agreement [Line Items]
Preferred stock, shares issued \| shares			0	0
Novartis License Agreement \| Novartis
License Agreement [Line Items]
Number of licensed compounds \| License		2
Number of licensed Product \| License		1
Upfront cash payment		$ 400,000
Total initial consideration transferred		3,400,000
Changes in fair value of anti dilution right liability			$ 0	$ 700,000
Aggregate milestone payments		231,700,000
Number of development milestone payments \| License			2
Development milestone payments			$ 1,000,000.0
Milestone payments achieved and paid						$ 600,000	$ 400,000
Novartis License Agreement \| Novartis \| Research and Development Expense
License Agreement [Line Items]
Initial fair value of anti-dilution right liability		$ 1,000,000.0
Novartis License Agreement \| Series A-1 Preferred Stock \| Maximum
License Agreement [Line Items]
Preferred stock, shares issued \| shares		6,383,142
Novartis License Agreement \| Series A-1 Preferred Stock \| Novartis
License Agreement [Line Items]
Preferred stock, shares issued \| shares		3,449,808
Fair value of stock		$ 3,000,000.0
Ownership interest		15.00%
Licensing milestone in sales of equity securities	$ 30,000,000.0	$ 30,000,000.0
Novartis License Agreement \| Series A-1 Preferred Stock \| Novartis \| Minimum
License Agreement [Line Items]
Licensing milestone in sales of equity securities		$ 30,000,000.0
Novartis License Agreement \| Series A-1 Preferred Stock \| Novartis \| Maximum
License Agreement [Line Items]
Preferred stock, shares issued \| shares					5,970,000

Redeemable Convertible Preferred Stock - Additional Information (Details) - shares	Dec. 31, 2022	Sep. 19, 2022	Dec. 31, 2021
Temporary Equity [Line Items]
Conversion of convertible preferred stock into common stock			21,967,316
Preferred Stock Outstanding			49,624,187
IPO
Temporary Equity [Line Items]
Conversion of convertible preferred stock into common stock		21,967,316
Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Outstanding	0
Common Stock \| IPO
Temporary Equity [Line Items]
Conversion of convertible preferred stock into common stock		21,967,316

Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Temporary Equity [Line Items]
Preferred Stock Authorized		49,624,190
Preferred Stock Issued		49,624,187
Preferred Stock Outstanding		49,624,187
Carrying Value		$ 170,184
Liquidation Value		$ 160,970
Common Stock Issuable Upon Conversion		21,967,316
Series A-1 Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		13,970,000
Preferred Stock Issued		13,970,000
Preferred Stock Outstanding		13,970,000
Carrying Value	$ 0	$ 12,574
Liquidation Value		$ 13,970
Common Stock Issuable Upon Conversion		6,184,150
Series A-2 Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		13,750,000
Preferred Stock Issued		13,750,000
Preferred Stock Outstanding		13,750,000
Carrying Value	$ 0	$ 19,476
Liquidation Value		$ 22,000
Common Stock Issuable Upon Conversion		6,086,762
Series A-3 Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		7,812,501
Preferred Stock Issued		7,812,501
Preferred Stock Outstanding		7,812,501
Carrying Value	$ 0	$ 33,288
Liquidation Value		$ 20,000
Common Stock Issuable Upon Conversion		3,458,386
Series B Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		14,091,689
Preferred Stock Issued		14,091,686
Preferred Stock Outstanding		14,091,686
Carrying Value		$ 104,846
Liquidation Value		$ 105,000
Common Stock Issuable Upon Conversion		6,238,018

Stockholder's Equity (Deficit) - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Sep. 19, 2022	Dec. 31, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Common Stock, Shares Authorized		500,000,000	72,731,000
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Common stock voting rights		one vote for each share
Common stock, cash dividends declared		$ 0	$ 0
Common Stock Shares Issued		39,377,222	4,237,290
Offering costs		$ 2,294	$ 0
Conversion of convertible preferred stock into common stock			21,967,316
Common Stock Shares Outstanding		39,377,222	4,237,290
Undesignated preferred stock, authorized		10,000,000	0
Preferred stock, Par Value		$ 0.0001	$ 0.0001
Undesignated preferred shares issued		0	0
Preferred shares outstanding		0	0
Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Undesignated preferred stock, authorized		10,000,000
IPO
Subsidiary, Sale of Stock [Line Items]
Common Stock, Shares Authorized	500,000,000
Initial public offering, Shares	12,535,000
Common Stock, Par or Stated Value Per Share	$ 0.0001
Public offering price	$ 17.00
Proceeds from issuing shares	$ 198,200
Offering costs	$ 2,300
Conversion of convertible preferred stock into common stock	21,967,316
Undesignated preferred stock, authorized	10,000,000
Preferred stock, Par Value	$ 0.0001
Over allotment \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Initial public offering, Shares	1,635,000

Stockholder's Equity (Deficit) - Schedule of Common Stock Reserved for Issuance (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
Conversion of outstanding shares of preferred stock	0	21,967,316
Options to purchase common stock	3,644,500	394,254
Unvested restricted common stock	964,992	1,907,102
Remaining shares reserved for future issuance	3,801,282	2,065,764
Total	8,410,774	26,334,436

Stock-Based Compensation - Additional Information (Details) - USD ($)					12 Months Ended
	Aug. 22, 2022	Nov. 15, 2021	Aug. 09, 2021	Feb. 24, 2021	Dec. 31, 2022	Dec. 31, 2021	Sep. 19, 2022	Sep. 14, 2022	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance					8,410,774	26,334,436
Stock-based compensation expense					$ 4,751,000	$ 510,000
CEO Promissory Note
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period					3 years
Special bonus paid	$ 1,900,000
Award vesting description					subject to a three-year vesting schedule with six-month cliffs
Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service period					3 months
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value per share of stock options					$ 8.27
Unrecognized stock-based compensation expense related to unvested stock options					$ 25,300,000
Unrecognized stock based compensation expense period of recognition					3 years 8 months 12 days
Fair value of options vested					$ 1,900,000
Outstanding stock options to purchase common stock					3,644,500	394,254
Share price						$ 1.90
Performance Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting over period					4 years
Stock-based compensation expense					$ 100,000	$ 0
Performance Stock Options \| Performance Based Vesting
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding stock options to purchase common stock						115,580			115,580
Performance Stock Options \| Series A-2 Second Tranche
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting of performance stock				37,133
Performance Stock Options \| Series A-3 Second Tranche
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting of remaining performance stock		97,938
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period					4 years
Unrecognized stock based compensation expense period of recognition					2 years 3 months 14 days
Stock-based compensation expense					$ 1,100,000
Share price					$ 0.0001
Remaining unrecognized expense	1,000,000.0
Weighted average grant date fair value					$ 0
Granted in period					0
Aggregate fair value of restricted stock awards vested					$ 700,000
Unrecognized expense					$ 1,200,000
Restricted Stock \| Promissory Note
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exchangeable value of shares purchased			$ 1,800,000
Restricted Stock \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share price			$ 1.44
Number of shares purchased			1,218,836
Special bonus paid	$ 1,900,000
Contingency period					12 months
Restricted Stock \| Chief Executive Officer [Member] \| Promissory Note
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Accrued Interest Rate			0.76%
2019 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common stock issuable under plan							5,317,559
Conversion of outstanding shares of preferred stock							283,808	283,808
Number of shares transferred					283,808
2022 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance					4,710,545
Maximum \| Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share price					$ 18.40
Maximum \| Performance Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 100,000
Maximum \| 2022 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of annual increase in number of shares to classes of common stock under plan					5.00%
Exercise price per share of stock options as percentage of fair market value of common stock					100.00%
Stock option expiration period					10 years
Minimum \| Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share price					$ 4.30

Stock-Based Compensation - Summary of Stock Options Valuation Assumptions (Details) - Stock Options - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	1.70%	0.87%
Risk-free interest rate	4.21%	1.20%
Expected dividend yield	0.00%	0.00%
Fair value of common stock		$ 1.90
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 6 months 10 days	6 years 6 months 10 days
Expected volatility	83.50%	84.20%
Fair value of common stock	$ 18.40
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	5 years 2 months 8 days	6 years 21 days
Expected volatility	72.80%	82.40%
Fair value of common stock	$ 4.30

Stock-Based Compensation - Summary of Stock Option Activity (Details) - Stock Options - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	394,254
Shares, Granted	3,448,476
Exercised	(13,283)
Forfeited or cancelled	(184,947)
Ending balance	3,644,500	394,254
Options vested and exercisable as of September 30, 2022	173,529
Options unvested as of September 30, 2022	3,470,971
Beginning balance	$ 0.85
Granted	11.41
Exercised	7.92
Forfeited or cancelled	8.19
Ending balance	10.45	$ 0.85
Options vested and exercisable as of September 30, 2022	6.82
Options unvested as of September 30, 2022	$ 10.70
Weighted-Average Remaining Contractual Term (in years)	9 years 6 months 3 days	9 years 29 days
Options vested and exercisable as of September 30, 2022	8 years 11 months 4 days
Aggregate Intrinsic Value	$ 1,283	$ 3,294
Options vested and exercisable as of September 30, 2022	581
Options unvested as of September 30, 2022	$ 769
Options unvested as of September 30, 2022	9 years 6 months 25 days

Stock-Based Compensation - Summary of Restricted Common Stock Activity (Details) - Restricted Stock	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance \| shares	1,907,102
Granted \| shares	0
Vested \| shares	(624,334)
Cancelled or forfeited \| shares	(317,776)
Ending balance \| shares	964,992
Beginning balance \| $ / shares	$ 1.17
Granted \| $ / shares	0
Vested \| $ / shares	1.33
Cancelled or forfeited \| $ / shares	0.71
Ending balance \| $ / shares	$ 0.59

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 4,751	$ 510
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,650	224
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 3,101	$ 286

Income Taxes - Income (Loss) Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Domestic	$ (35,155)	$ (29,609)
Foreign	0	0
Loss before provision for income taxes	$ (35,155)	$ (29,609)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Reconciliation of Company's Statutory Income Tax Rate and Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Income at US statutory rate	21.00%	21.00%
State taxes, net of federal benefit	3.60%	3.43%
Change in tranche liability	0.00%	(7.04%)
Non-deductible Compensation	(3.31%)	(0.21%)
Tax credits	0.50%	1.03%
Valuation allowance	(21.78%)	(18.21%)
Other	(0.01%)	0.00%
Effective income tax rate reconciliation, percent, total	(0.00%)	0.00%

Income Taxes - Summary of Net Deferred Income Tax Asset Balance (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Components of Deferred Tax Assets [Abstract]
Net operating loss carryforwards	$ 10,336	$ 7,935
Research and development credits	1,006	774
Intangibles	1,422	1,613
Capitalized research and development	5,433	0
Right of use liabilities	1,087	0
Stock-based compensation	211	0
Accrued expenses & other	274	252
Total deferred tax assets	19,769	10,574
Right of use assets	(1,084)	0
Deferred compensation	(445)	0
Other	0	0
Total deferred tax liabilities	(1,529)	0
Net Deferred Tax assets	18,240	10,574
Valuation allowance	(18,240)	(10,574)
Deferred Tax Assets, Net of Valuation Allowance	$ 0	$ 0

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Federal net operating loss carryforward	$ 38,900,000	$ 29,800,000
State net operating loss carryforwards	34,100,000	26,700,000
Deferred tax assets provision	5,400,000
Uncertain tax positions	0	0
Accrued interest or penalties related to tax liability	$ 0	$ 0
Income tax examination, Description	The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company’s tax years are still open under statute from December 31, 2019, to the present.
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Credits	$ 800,000
Tax credits begin to expire year	2039
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Net operating loss carryforwards begin to expire year	2039
Credits	$ 200,000
Tax credits begin to expire year	2039

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Net loss	$ 35,155	$ 29,609
Net loss attributable to common stockholders, basic	35,155	29,609
Net loss attributable to common stockholders, diluted	$ 35,155	$ 29,609
Weighted-average number of common shares used in net loss per share, basic	13,426,066	4,043,416
Weighted-average number of common shares used in net loss per share, diluted	13,426,066	4,043,416
Net loss per share of common stock, basic	$ 2.62	$ 7.32
Net loss per share of common stock, diluted	$ 2.62	$ 7.32

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.

+ References + Details

Net Loss Per Share - Schedule of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-dilutive Effect (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti diluted effect of diluted net loss per share	4,609,492	24,268,672
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti diluted effect of diluted net loss per share	0	21,967,316
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti diluted effect of diluted net loss per share	3,644,500	394,254
Unvested Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti diluted effect of diluted net loss per share	964,992	1,907,102

Leases - Additional Information (Details)	1 Months Ended
Leases - Additional Information (Details)	Oct. 31, 2022 USD ($) ft²	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Leases [Line Items]
Operating lease right of use assets \| $	$ 0
Operating lease liabilities \| $	$ 0	$ 385,000	$ 0
130 Prospect Street in Cambridge, Massachusetts
Leases [Line Items]
Area of land \| ft²	10,356
Lease commencement date	Dec. 01, 2022
Initial lease term	63 months
Lease expiring date	Feb. 29, 2028
1700 Montgomery Street in San Francisco, California
Leases [Line Items]
Area of land \| ft²	4,703
Lease commencement date	Dec. 20, 2022
Initial lease term	63 months
Lease expiring date	Feb. 20, 2028

Leases - Components of Operating Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lease, Cost [Abstract]
Lease Cost:	$ 0	$ 0
Operating lease cost	75	0
Variable operating lease cost	0	0
Short-term operating lease cost	195	97
Total operating lease cost	$ 270	$ 97

Leases - Summary of Information Related to Measurement of Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term	5 years 2 months 12 days	0 years
Weighted-average discount rate	10.50%	0.00%
Cash paid for amounts included in the measurement of operating lease liabilities	$ 0	$ 0

Leases - Maturities of Operating Lease Liabilities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Lessee, Operating Lease, Liability, to be Paid [Abstract]
2023	$ 826
2024	1,116
2025	1,145
2026	1,176
Thereafter	1,445
Total lease payments	5,708
Less: interest	(1,369)
Total lease liability	$ 4,339

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands			12 Months Ended
	Aug. 22, 2022	Aug. 09, 2021	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Common stock issued (in shares)			39,377,222	4,237,290
Stock-based compensation expense			$ 4,751	$ 510
General and Administrative
Related Party Transaction [Line Items]
Stock-based compensation expense			3,101	286
Atlas Venture Fund XI, L.P \| General and Administrative
Related Party Transaction [Line Items]
Related party transaction payment			$ 100	$ 200
Atlas Venture Fund XI, L.P \| Minimum
Related Party Transaction [Line Items]
Outstanding stock percentage			5.00%	5.00%
Novartis \| Minimum
Related Party Transaction [Line Items]
Outstanding stock percentage			5.00%	5.00%
CEO Promissory Note
Related Party Transaction [Line Items]
Promissory note agreement amount		$ 1,800
Common stock issued (in shares)		1,218,836
Interest rate of promissory note		0.76%
Special bonus paid	$ 1,900
Vesting period			3 years
Award vesting description			subject to a three-year vesting schedule with six-month cliffs

Subsequent Events - Additional Information (Details) - 2019 and 2022 plan - Subsequent Events	Mar. 06, 2023 $ / shares
Subsequent Event [Line Items]
Repriced of exercise price	$ 4.20
Minimum
Subsequent Event [Line Items]
Exercise price	$ 8.61